The life science and biotech PR distribution service

Heiner Dreismann Joins Noscendo’s Board of Directors

Noscendo logo v2

DUISBURG, Germany, October 05, 2021 / B3C newswire / -- Noscendo GmbH, a leading diagnostic company for identification and assessment of bloodstream associated pathogens and other infections announced today the addition of Heiner Dreismann, former President and CEO of Roche Molecular Systems, to its Board of Directors.

Dr. Dreismann, a microbiologist by training, contributed significantly to the development and commercialization of an extensive portfolio of products within the microbiology space, among others, enforcing Roche’s industry leadership in Molecular Diagnostics. Other senior positions he held in Roche included Head of Global Business Development, Roche Diagnostics and Member of Roche's Global Diagnostic Executive Committee adding tremendous market understanding to Noscendo’s Board of Directors.

„We are thrilled to welcome Dr. Dreismann to the Board of Directors, with his tremendous experience in the area of molecular microbiology and the diagnostic market overall he adds valuable market insight to the Board of Directors.”, said Dr. Philip Stevens, Managing Director of Noscendo GmbH. “We are pleased to be able to draw on Dr. Dreismann's invaluable experience to strengthen our leading position in next-generation medical microbiology and create the long-awaited change in medical microbiology.”

„I am very excited to join the board of directors of Noscendo.” said Dr. Heiner Dreismann. “The clinical microbiology space will benefit significantly from the disruptive technology and business model innovation Noscendo is providing by applying its proprietary Artificial Intelligence derived algorithms for a deep analysis of sequence based information. In particular, the breadth and versatility of its current and future product pipeline is unparalleled.”


About Noscendo GmbH
Noscendo GmbH develops bioinformatic solutions to identify and assess pathogens in bloodstream associated and related infections. The proprietary diagnostic platform has been validated together with leading German clinicians and will be provided in the area of bloodstream infections. For this, Noscendo works together with leading hospitals, development partners, logistics providers, innovation-driven health service providers and health insurance funds. 

The DISQVER® platform ensures effective, fast and reliable sample analysis using next generation sequencing (NGS) and Noscendo´s proprietary bioinformatic software algorithm. This enables the reliable detection of more than 1.500 bacteria, DNA viruses, fungi and parasites in the patient’s bloodstream based on cell free DNA (cfDNA). Such pathogens are responsible for many life-threatening diseases such as sepsis, pneumonia such in the case of COVID-19 and antimicrobial resistance where full and reliable detection is key for survival and appropriate treatment.



Noscendo GmbH
Dr. Philip Stevens
Königstrasse 34
47198 Duisburg
+49 (0)2066-5068780
This email address is being protected from spambots. You need JavaScript enabled to view it.


Keywords: Humans; Bacteria; Infections; High-Throughput Nucleotide Sequencing; Reagent Kits, Diagnostic; Blood; Drug Resistance, Microbial; Drug Resistance, Bacterial; Software; Artificial Intelligence; Computational Biology; Cell-Free Nucleic Acids; DNA; Fungi; Viruses; Bacteria; DNA Viruses; Parasites; Physicians; Hospitals; Sepsis; Leadership; Germany


Published by B3C newswire

Cookies make it easier for us to provide you with our services. With the usage of our services you permit us to use cookies.